J2H 1702
Alternative Names: J2H-1702Latest Information Update: 18 Mar 2024
At a glance
- Originator J2H Biotech
- Class Hepatoprotectants; Small molecules
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
Most Recent Events
- 18 Mar 2024 J2H Biotech completes a phase I pharmacokinetic trial in Non alcoholic steatohepatit (In Volunteers) in South Korea (PO) (NCT06308861)
- 17 Feb 2024 J2H Biotech initiates a phase I pharmacokinetic trial in Non-alcoholic Steatohepatitis (In volunteers, In adults) in South Korea (PO) (NCT06308874)
- 02 Jan 2023 J2H Biotech initiates a phase I pharmacokinetic trial in Non-alcoholic Steatohepatitis (In volunteers, In adults) in South Korea (PO) (NCT06308874)